Page 148 - ஜெர்மன் கூட்டாட்சியின் அமைச்சகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Feb 25, 2021 Earlier diagnosis may be key to effective treatment A tau-directed monoclonal antibody did not slow the advancement of progressive supranuclear palsy (PSP), a phase II study found. “Tilavonemab a monoclonal antibody that binds an epitope containing amino acids 25–30 at the N-terminus of tau in doses high enough to bind 50% or more of tau in the cerebrospinal fluid did not affect progression of the disorder,” wrote Gunter Hoglinger, MD, of Hannover Medical School in Germany, and co-authors in Hoglinger and colleagues conducted a randomized, placebo-controlled, double-blind study at 66 international sites. The trial was terminated after pre-specified futility criteria were met by the second interim analysis.

Gunter hoglingerPaul smythDeutsche forschungsgemeinschaftVolkswagenstiftung lower saxony ministry for science petermaxGerman federal ministry of educationInnovative medicines initiative jointHannover medical schoolGerman centerProgressive supranuclear palsy rating scaleContributing writerNeurodegenerative diseasesGerman federal ministryParkinsonfonds germanyInnovative medicines initiative joint undertakingLower saxony ministryபால் ஸ்மித்